Performance of DNLI Denali Therapeutics | -34.9% in 12m
Compare DNLI with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Denali Therapeutics with its related Sector/Index XBI
Performance Duell DNLI vs XBI
| TimeFrame | DNLI | XBI |
|---|---|---|
| 1 Day | 5.62% | 2.02% |
| 1 Week | 10.4% | 3.93% |
| 1 Month | 16.9% | 7.25% |
| 3 Months | 13.6% | -0.71% |
| 6 Months | 12.9% | 30.27% |
| 12 Months | -34.9% | 5.80% |
| YTD | -2.48% | 2.64% |
| Rel. Perf. 1m | 0.69 | |
| Rel. Perf. 3m | -0.87 | |
| Rel. Perf. 6m | -1.29 | |
| Rel. Perf. 12m | -4.41 |
Is Denali Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Denali Therapeutics (NASDAQ:DNLI) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -60.35 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DNLI as of May 2024 is 17.68. This means that DNLI is currently overvalued and has a potential downside of -15.24% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DNLI as of May 2024 is 17.68. This means that DNLI is currently overvalued and has a potential downside of -15.24% (Sold with Premium).
Is DNLI a buy, sell or hold?
- Strong Buy: 11
- Buy: 4
- Hold: 2
- Sell: 0
- Strong Sell: 0
Values above 0%: DNLI is performing better - Values below 0%: DNLI is underperforming
Compare DNLI with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 7.94% | 11.91% | -5.78% | -64.98% |
| US NASDAQ 100 | QQQ | 7.45% | 11.86% | -5.02% | -74.37% |
| US Dow Jones Industrial 30 | DIA | 8.12% | 11.00% | -2.18% | -56.79% |
| German DAX 40 | DBXD | 8.39% | 12.44% | -6.57% | -52.97% |
| UK FTSE 100 | ISFU | 7.81% | 8.82% | -3.98% | -48.84% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 9.85% | 13.25% | 12.01% | -23.75% |
| Hongkong Hang Seng | HSI | 4.57% | -1.40% | 11.55% | -24.97% |
| Japan Nikkei 225 | EXX7 | 10.44% | 21.14% | 0.81% | -48.42% |
| India NIFTY 50 | INDA | 9.77% | 14.84% | -3.56% | -60.70% |
| Brasil Bovespa | EWZ | 12.75% | 14.27% | 15.41% | -46.16% |
DNLI Denali Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 8.81% | 14.15% | -6.02% | -73.70% |
| Consumer Discretionary | XLY | 9.75% | 14.18% | 5.78% | -56.69% |
| Consumer Staples | XLP | 9.35% | 11.16% | 1.51% | -38.27% |
| Energy | XLE | 9.50% | 18.32% | -0.10% | -57.96% |
| Financial | XLF | 8.39% | 11.11% | -9.77% | -68.35% |
| Health Care | XLV | 7.47% | 11.47% | -2.30% | -47.46% |
| Industrial | XLI | 9.09% | 13.72% | -8.18% | -64.25% |
| Materials | XLB | 8.93% | 14.09% | -3.55% | -54.10% |
| Real Estate | XLRE | 5.62% | 10.81% | 3.19% | -43.48% |
| Technology | XLK | 6.37% | 11.22% | -4.45% | -75.96% |
| Utilities | XLU | 7.15% | 2.91% | -6.59% | -44.92% |
| Aerospace & Defense | XAR | 9.10% | 8.93% | -1.60% | -60.93% |
| Biotech | XBI | 6.44% | 9.68% | -17.39% | -40.65% |
| Homebuilder | XHB | 6.03% | 10.01% | -22.46% | -90.22% |
| Retail | XRT | 4.90% | 7.70% | -9.52% | -63.09% |
Does Denali Therapeutics outperform its market, is DNLI a Sector Leader?
No, over the last 12 months Denali Therapeutics (DNLI) made -34.85%, while its related Sector, the SPDR S&P Biotech (XBI) made 5.80%.
Over the last 3 months DNLI made 13.62%, while XBI made -0.71%.
No, over the last 12 months Denali Therapeutics (DNLI) made -34.85%, while its related Sector, the SPDR S&P Biotech (XBI) made 5.80%.
Over the last 3 months DNLI made 13.62%, while XBI made -0.71%.
| Period | DNLI | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 16.93% | 7.25% | 5.02% |
| 3 Months | 13.62% | -0.71% | 5.86% |
| 12 Months | -34.85% | 5.80% | 30.13% |